• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, November 17, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Biology

Regional Multi-Omic Framework Resolves Diagnostic Gaps in Pediatric Neurogenetic Disease

by
November 17, 2026
in Biology
Reading Time: 6 mins read
0
Regional Multi-Omic Framework Resolves Diagnostic Gaps in Pediatric Neurogenetic Disease

Regional Multi-Omic Framework Resolves Diagnostic Gaps in Pediatric Neurogenetic Disease

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

In an implementation perspective published in Frontiers in Genetics, researchers from the University of Utah School of Medicine and Primary Children’s Hospital have detailed a regional clinical framework designed to resolve undiagnosed pediatric neurogenetic conditions by integrating short-read genome sequencing with transcriptomic and long-read sequencing technologies. Although clinical short-read genome sequencing has become the recommended first-tier investigation for pediatric neurodevelopmental disorders and critically ill infants, its diagnostic yield consistently plateaus near forty percent across broad clinical cohorts, leaving most evaluated families without answers. To address this diagnostic plateau across a largely rural, underserved catchment area spanning the Mountain West, the investigative team established an integrated clinical and laboratory architecture linking universal front-end genome sequencing with continuous computational surveillance and a standardized reanalysis pipeline. Rather than presenting prospective cohort outcome statistics or diagnostic efficacy rates, which are documented in separate studies, the perspective articulates the organizational, logistical, and computational methodologies necessary to transform multi-omic investigations from ad hoc research efforts into an equitable, routine standard of healthcare delivery.

The authors emphasize that the undiagnosed fraction following initial short-read genome sequencing does not stem from a uniform biological failure, but represents a diverse collection of mechanistically distinct molecular lesions that evade detection or functional interpretation on standard short-read platforms. In pediatric neurology cohorts, standard short-read sequencing achieves diagnostic yields of roughly twenty-five to forty percent, with reported yields in neonatal intensive care units varying from approximately twenty percent in randomized trials of rapid sequencing to over forty percent in selected cohorts. The remaining unsolved cases encompass several discrete diagnostic hurdles, including non-coding variants located within deep intronic, promoter, or untranslated regions that alter gene expression or pre-messenger RNA splicing without altering the encoded protein sequence. Furthermore, standard short-read sequencing approaches struggle to detect short tandem repeat expansions, balanced chromosomal structural rearrangements, mobile transposable element insertions, and sequence variations situated within segmentally duplicated or inaccessible genomic regions. A third subset of inconclusive outcomes arises from variants of uncertain significance where novel gene-disease associations await discovery.

To overcome these distinct molecular limitations, the Utah framework strategically layers short-read genome sequencing with complementary RNA sequencing and long-read sequencing technologies, with each modality addressing the specific blind spots of the others. Transcriptome sequencing through RNA-seq serves as a decisive diagnostic instrument for identifying aberrant splicing events, such as pseudoexon inclusion, cryptic splice-site activation, and exon skipping, while simultaneously profiling allele-specific expression, expression outliers, and nonsense-mediated mRNA decay. Previous empirical investigations cited by the authors indicate that blood-based RNA sequencing identifies a plausible candidate in approximately seven percent of previously undiagnosed pediatric genome cases. Conversely, long-read DNA sequencing directly addresses read-length constraints, providing robust resolution of short tandem repeat expansions, complex or balanced structural rearrangements, and diploid phasing, while accessing genomic regions historically obscured on short-read platforms. Across unsolved cohorts following negative short-read genome sequencing, long-read sequencing adds approximately seven to seventeen percent diagnostic yield, with pediatric series yielding closer to five percent, though long-read sequencing currently entails higher per-sample costs and lower throughput.

The front end of the regional pathway begins with specialized clinical initiatives structured to standardize initial genomic testing and deliberately facilitate downstream multi-omic escalation. The earliest foundational element, the NeoSeq Project, was established in January 2020 within the University of Utah neonatal intensive care unit to bridge academic research with certified clinical laboratory workflows delivered to families at no cost. Between January 2020 and April 2023, the NeoSeq program enrolled sixty-five complex neonatal cases, comprising sixty trios, four duos, and one quad. By standardizing multidisciplinary short-read genome delivery at the point of care, NeoSeq generated a reproducible pipeline of well-phenotyped negative genomes for future multi-omic reanalysis. The authors assert that genomic testing programs must intentionally anticipate the undiagnosed majority from inception, ensuring that technical escalations toward transcriptomics and long-read sequencing are structurally embedded within routine clinical pathways rather than retrofitted as fragmented interventions after years of protracted diagnostic delay.

To prevent geographic disparities from restricting access to clinical genetics expertise, the pathway incorporates TeleGenetics, a remote consultation program launched in January 2024 across six regional sites. TeleGenetics serves inpatient neonates admitted to Level II and Level III community neonatal intensive care units throughout Utah who do not require transfer to a quaternary pediatric hospital, but who nevertheless present with suspected Mendelian disease. Between January 2024 and June 2026, the TeleGenetics program completed ninety patient encounters. Remote geneticists conduct structured virtual dysmorphology and neurological assessments in real-time collaboration with local bedside clinicians who perform physical examination maneuvers, including muscle tone evaluation, palpation, and reflex testing. Dedicated genetic counselors support the remote service by managing complex operational barriers, such as navigating diagnostic requisitions, specimen processing logistics, sample transport routing, and insurance prior authorizations, thereby enabling community medical centers lacking resident genetics specialists to deliver standardized, expert genomic diagnostics.

Recognizing that specialist-dependent referrals and commercial insurance limitations often systematically exclude underserved populations, the institutional partnership established the Gene Kids program in September 2024. Operating as an endowment-funded regional hub-and-spoke delivery system across thirty-one clinical sites located in six states, Gene Kids provides first-line short-read genome sequencing for pediatric patients with suspected genetic disorders. Since its implementation, the initiative has enrolled 3,135 individuals, consisting of 2,000 probands and 1,135 parents, and has successfully compressed institutional wait-times for medical genetic consultations from over six months down to approximately 1.5 months. Crucially, Gene Kids utilizes a parallel dual-stream financial model: patients with adequate health insurance obtain testing through routine clinical laboratories, whereas uninsured and underinsured families receive fully subsidized testing through programmatic funding. By removing personal payer ability as an inclusion gate, the pathway ensures that the downstream cohort of undiagnosed individuals evaluated by advanced multi-omics genuinely reflects the demographic and socioeconomic composition of the broader regional population.

To eliminate human referral variability and bias upstream of genetic evaluation, the regional health system integrated automated artificial intelligence surveillance using the Mendelian Phenotype Search Engine, or MPSE. Initiated in May 2025 within the University of Utah neonatal intensive care unit, MPSE combines clinical natural language processing algorithms with machine learning classifiers to extract unstructured notes from the electronic health record, convert documented phenotypic descriptions into standardized Human Phenotype Ontology terms, and generate objective prioritization scores. Between May and December 2025, the automated surveillance system screened 205 neonatal intensive care admissions, with preliminary operational evaluations demonstrating a measurable reduction in the elapsed time from initial admission to genetic test ordering. Because conventional inpatient genetics consults depend heavily on individual clinician familiarity with rare diseases and competing clinical demands, automated surveillance ensures objective screening across all admissions, with ongoing technical efforts actively underway to expand MPSE deployment into pediatric and cardiac intensive care units.

Non-diagnostic genomes generated across these front-end programs transition directly into the Neo/ReSeq reanalysis engine, a prospective institutional research protocol established in September 2022 that has accrued ninety-two pediatric cases. Conducted as a formal partnership between the Utah Center for Genetic Discovery and ARUP Laboratories, Neo/ReSeq applies structured multi-omic workflows governed by objective clinical criteria. The initial operational phase reanalyzes existing raw sequencing data against updated population allele frequencies from gnomAD, curated clinical variant databases including ClinVar and OMIM, revised ACMG and AMP pathogenicity guidelines, and computational splice-prediction tools such as SpliceAI and MaxEntScan. When reanalysis flags candidate splice-altering or regulatory variants, cases advance to RNA sequencing; conversely, when phenotypes strongly indicate repeat expansions or structural rearrangements, cases receive long-read sequencing. Rather than enforcing an inflexible sequential testing hierarchy, the program frequently executes transcriptomic and long-read assays concurrently during weekly multidisciplinary case conferences, preventing unnecessary diagnostic delays.

The perspective highlights source-tissue selection as a critical operational determinant dictating whether RNA sequencing succeeds as a functional diagnostic tool. While peripheral blood represents the most clinically accessible specimen, numerous neurodevelopmental disease genes exhibit tissue-restricted expression profiles and remain functionally silent in circulating leukocytes. Consequently, blood-derived transcriptomic assays frequently fail to identify pathogenic splice aberrations or expression abnormalities occurring in inaccessible tissues. The Utah protocol prospectively defaults to blood collection but obtains skin fibroblasts or affected tissue biopsies, coordinating collections opportunistically when pediatric patients undergo planned clinical procedures or sedation. Furthermore, the authors underscore that certain critical developmental genes, including homeobox clusters and the pluripotency regulator POU5F1, or OCT4, are strictly transcribed during early embryogenesis and repressed in differentiated postnatal tissues. To resolve variants within such temporally restricted loci, future clinical workflows will increasingly require disease-relevant cellular models, such as patient-derived induced pluripotent stem cells differentiated toward affected neural lineages.

The long-term delivery of clinical multi-omics relies on shared institutional infrastructure, including a unified bioinformatic processing framework, weekly multidisciplinary case review conferences, certified laboratory collaborations, and a secure data repository that co-localizes genomic, transcriptomic, and long-read datasets for longitudinal re-evaluation. The authors note, however, that several operational limitations persist, including reliance on a uniquely integrated regional medical ecosystem, incomplete representation of diverse ancestral populations within genomic reference databases, and the ongoing necessity of sustained funding to support testing for uninsured families. Looking forward, the regional architecture is modularly designed to incorporate emerging diagnostic methodologies, such as optical genome mapping, methylation and episignature profiling, and long-read transcriptomics, alongside stem cell modeling for inaccessible tissues. Ultimately, the perspective demonstrates that closing the pediatric neurogenetic diagnostic gap requires systematic organizational coordination, automated clinical surveillance, and egalitarian clinical delivery, ensuring that transformative multi-omic technologies reach all undiagnosed children rather than remaining restricted to well-resourced academic centers.

Subject of Research: Clinical implementation of an integrated multi-omic diagnostic pathway for undiagnosed pediatric neurogenetic disease

Article Title: Implementation of a standardized, equitable multi-omic pathway to resolve undiagnosed pediatric neurogenetic disease

Article References: Shayota, B. J., Emmerson, M., Palmquist, R. N., Solorzano, C. M., Bayrak-Toydemir, P., Beigh, M., Bleyl, S. B., Boyden, S. E., Clark, E., Ellsworth, T., Happ, H., Hernandez-Ruiz, J., Holt, C. H., Larson, J., Mao, R., Marchetti, M., Moore, B., Nicholas, T. J., Ostrander, B., … Malone Jenkins, S. (2026). Implementation of a standardized, equitable multi-omic pathway to resolve undiagnosed pediatric neurogenetic disease. Frontiers in Genetics, 17, Article 1955129. https://doi.org/10.3389/fgene.2026.1955129

Image Credits: AI Generated

DOI: 10.3389/fgene.2026.1955129

Keywords: pediatric neurogenetics, short-read genome sequencing, RNA sequencing, long-read sequencing, multi-omics, NeoSeq, TeleGenetics, Gene Kids, Mendelian Phenotype Search Engine, Neo/ReSeq, diagnostic yield, cryptic splicing, structural variants, health equity, neonatal intensive care, rare disease

News Source: Harold Sullivan. (November 17, 2026). Regional Multi-Omic Framework Resolves Diagnostic Gaps in Pediatric Neurogenetic Disease. Scienmag.

Tags: cryptic splicingdiagnostic yieldGene Kidshealth equitylong-read sequencingMendelian Phenotype Search Enginemulti-omicsNeo/ReSeqneonatal intensive careNeoSeqpediatric neurogeneticsrare diseaseRNA sequencingshort-read genome sequencingstructural variantsTeleGenetics
Share12Tweet7Share2ShareShareShare1

Related Posts

South Korean Cattle Study Identifies Common Cryptosporidium and Eimeria Parasite Subtypes

South Korean Cattle Study Identifies Common Cryptosporidium and Eimeria Parasite Subtypes

November 17, 2026
Simmental Bull Semen Preservation at Zero Degrees Celsius Optimised by One-to-Five Dilution

Simmental Bull Semen Preservation at Zero Degrees Celsius Optimised by One-to-Five Dilution

November 17, 2026

USP2 Stabilizes c-Fos to Drive AP-1 Transcription in Breast Cancer

November 17, 2026

Dynamic Multi-Objective Optimization Algorithm Improves Detection of Cancer Critical Biomarkers

November 17, 2026

POPULAR NEWS

  • Mobile Health Units With Community Workers Address Critical Hypertension Care Gaps

    Mobile Health Units With Community Workers Address Critical Hypertension Care Gaps

    29 shares
    Share 12 Tweet 7
  • Brazilian EQ-5D Mapping Algorithm Offers Alternative to European-Based Standards

    29 shares
    Share 12 Tweet 7
  • Self-Assembled Berberine-Gallic Acid Nanorods Ameliorate Ulcerative Colitis in Mice

    29 shares
    Share 12 Tweet 7
  • Tablet Augmented Reality System May Reduce Preoperative Anxiety in Pediatric Surgical Patients

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Four Key Clinical Factors Associated With Heart Injury in Gastrointestinal Bleeding

Nanjing Hospital Study Finds 19.2 Percent HPV Positivity Among 39,335 Women

Specialized EBI3-High Dendritic Cell Subset Identified in Rheumatoid Arthritis Synovial Fluid

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.